Dou Changlin
窦昌林
R&D President and Chief Operating Officer, Boan Biotech
博安生物研发总裁兼首席运营官
Dr. Changlin Dou is the founder of Boan Biotech. He established Boan’s discovery and CMC development platforms and has successfully brought 3 antibody products to market in China and 9 products to clinical development in China, US, Europe, and Japan. Prior to returning to China in 2012 to start Boan Biotech, Dr. Dou worked on cell line and process development at several leading biotechnology and life science companies, including Regeneron, Genentech, and Life Technologies. He obtained his BS degree from Peking University and PhD degree from State University of New York at Stony Brook and conducted postdoctoral research at Memorial Sloan-Kettering Cancer Center.
Dr. Dou has published 26 peer-reviewed papers in international journals (highest impact factor 38). He is an inventor of 2 issued US patents, 15 issued CN patents, 7 pending PCT patents, 13 pending CN patents and 9 pending JP/EP/US/BR/CA/AU/US patents on novel protein expression technologies and new biologic products.
窦昌林博士是博安生物创始人，主导建立了公司的抗体药物发现与CMC（化学、生产与质量控制）开发平台，并成功推动3款抗体产品在中国上市，同时有9款产品进入中国、美国、欧洲和日本的临床开发阶段。
在2012年回国创办博安生物之前，窦博士曾在多家全球领先的生物技术与生命科学公司工作，包括Regeneron、Genentech 和 Life Technologies，主要从事细胞株构建与工艺开发工作。他本科毕业于北京大学，随后在美国纽约州立大学石溪分校获得博士学位，并在斯隆-凯特琳癌症中心完成博士后研究。
窦博士在国际学术期刊上发表了26篇同行评审论文，在蛋白表达新技术及生物创新药方面拥有广泛的知识产权成果，包括：2项已授权的美国专利，15项已授权的中国专利，7项PCT专利申请，13项中国专利申请，9项日本/欧洲/美国/巴西/加拿大/澳大利亚等国家和地区的专利申请。
他致力于研究与创新中国抗体药物开发产业化进程，并引领生物制药领域技术突破。
